Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: D K Grove / Shutterstock.com Ford (NYSE: F ) stock is losing traction on Monday after UBS analyst Patrick Hummel hit the automobile company’s shares with a downgrade . That downgrade sees...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX ) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering . Immati...
German biotech Immatics N.V. ( NASDAQ: IMTX ) announced interim data for its solid tumor candidate IMA203 on Monday, indicating the potential of the TCR-engineered cell therapy as a multi-tumor target in a Phase 1 trial. IMTX shares added ~11% in the morning hours Mond...
Immatics ( NASDAQ: IMTX ) is selling 10,905,000 of its ordinary shares at a price of $10.09/share in an underwritten public offering . Gross proceeds from the offering are expected to be ~$110M. The offering is expected to close on Oct 12, 2022. For further detai...
H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, an...
Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large poten...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
TCER ® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as par...
IMA203CD8 is a 2 nd -generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-tumor activity...
Immatics press release ( NASDAQ: IMTX ): Q2 GAAP EPS of -€0.22 Collaboration Revenue of €17.21M (+231.6% Y/Y) Cash and cash equivalents as well as other financial assets total €324.4 million ($337.0 million) as of June 30, 2022, compared to ...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...